Step 1 topics → Endocrine → Insulin Preparations (Rapid, Short, Intermediate, Long)

Insulin Preparations (Rapid, Short, Intermediate, Long)

USMLE Step 1 trap: Confuses long-acting insulin (peakless) with intermediate-acting NPH (has a peak), increasing hypoglycemia risk misattribution. Glargine and detemir provide a peakless, flat 24-hour basal profile, unlike NPH which has a distinct peak at 4–10 hours.

Insulin preparations are one of the highest-yield pharmacology topics on USMLE Step 1, and for good reason — they show up in clinical vignettes requiring you to match insulin type to timing, identify adverse effects, and understand the underlying physiology. The exam tests this from multiple angles: pure recall (which insulin has the longest duration?), application (a patient on NPH develops hypoglycemia in the afternoon — why?), and passage interpretation (a DKA patient is given insulin IV and potassium drops — what's the mechanism?). You need to know the four major classes cold: rapid-acting analogs (lispro, aspart), short-acting regular insulin, intermediate-acting NPH, and long-acting analogs (glargine, detemir, degludec).

What makes this topic tricky is that students conflate classes that seem similar. The biggest traps involve NPH versus glargine — both are 'background' insulins in people's minds, but they behave very differently. NPH has a real peak at 4–10 hours that can cause predictable hypoglycemia mid-day or overnight; glargine and detemir are designed to be essentially peakless, providing flat basal coverage for 24 hours. The other major trap is pre-meal timing: lispro and aspart are given right before eating because they kick in within 15 minutes, while regular insulin needs a 30-minute head start. Getting this backwards on a vignette means choosing the wrong management answer.

The third angle USMLE Step 1 hammers is insulin's effect on potassium. Insulin causes hypokalemia — but not through the kidneys. It works by activating Na+/K+-ATPase, pushing K+ intracellularly. This is clinically exploited when treating hyperkalemia (give insulin + dextrose). Students who misattribute this to renal excretion will struggle with both the pharmacology and the physiology questions that follow from it.

From real student decks
95%have cards covering this topic
81%have mature cards
2median lapses in 14 days

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: Long-acting insulins (glargine, detemir) have a peak effect like intermediate-acting NPH.
Right: Glargine and detemir provide a peakless, flat 24-hour basal profile, unlike NPH which has a distinct peak at 4–10 hours.
NPH and glargine are both used for basal coverage, but their pharmacokinetic profiles are fundamentally different. NPH has a distinct peak around 4–10 hours after injection, meaning a patient injected in the morning can become hypoglycemic in the early afternoon — this is predictable and testable. Glargine (and detemir) are engineered to precipitate slowly in subcutaneous tissue and release at a constant rate, producing a flat, peakless profile over ~24 hours. When a vignette asks why a patient on long-acting insulin is having nighttime hypoglycemia, think about whether they might actually be on NPH, not glargine.
Common mistake
Wrong: Insulin causes hypokalemia by increasing renal potassium excretion.
Right: Insulin drives potassium into cells by stimulating Na+/K+-ATPase, causing hypokalemia through intracellular shift, not renal loss.
Insulin's effect on potassium is entirely intracellular — it stimulates Na+/K+-ATPase on skeletal muscle and other cells, driving K+ from the extracellular space into cells. This is completely separate from renal handling of potassium. The clinical proof: we use insulin + dextrose (to prevent hypoglycemia) as an acute treatment for life-threatening hyperkalemia, precisely because it rapidly shifts K+ intracellularly within 15–30 minutes. If the mechanism were renal, it would be too slow and the patient would be urinating — neither of which fits the clinical picture.
Common mistake
Wrong: Regular insulin and rapid-acting analogs (lispro, aspart) are given at the same time relative to meals.
Right: Rapid-acting analogs (lispro, aspart) are given immediately before meals due to their fast onset (~15 min), while regular insulin is given 30 minutes before meals.
The timing difference exists because of fundamentally different pharmacokinetics. Rapid-acting analogs (lispro, aspart) are modified so they don't form hexamers and absorb almost immediately, with onset around 15 minutes — so you inject them right as you sit down to eat. Regular insulin forms hexamers that must dissociate before absorption, delaying onset to 30–60 minutes. Giving regular insulin at mealtime or lispro 30 minutes before a meal both create mismatches between insulin peak and glucose absorption, leading to either post-meal hyperglycemia or pre-meal hypoglycemia. On Step 1, a question about dosing timing almost always hinges on this distinction.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the onset, peak, and duration for each insulin class: rapid-acting analogs (onset ~15 min, peak 1–2 hr), regular insulin (onset 30–60 min, peak 2–4 hr), NPH (onset 2–4 hr, peak 4–10 hr, duration ~18 hr), and long-acting analogs like glargine/detemir (onset 2–4 hr, no significant peak, duration up to 24 hr or longer for degludec).
  2. Understand insulin receptor signaling: insulin binds a tyrosine kinase receptor, triggering downstream effects including GLUT4 translocation to muscle and fat, glycogen synthesis, lipogenesis, and inhibition of gluconeogenesis — and specifically the stimulation of Na+/K+-ATPase causing intracellular potassium shift.
  3. Recognize and explain the adverse effects of insulin therapy, especially hypoglycemia (most common and dangerous) and hypokalemia (via intracellular shift), and know that lipohypertrophy occurs at repeated injection sites.

Can you avoid these mistakes?

A patient with type 1 diabetes is started on NPH insulin every morning. She calls her doctor at 3 PM reporting shakiness and diaphoresis. Which property of NPH is responsible for this complication, and why would glargine have been less likely to cause it?
A patient in the ICU with severe hyperkalemia (K+ = 6.8 mEq/L) is given IV insulin and dextrose. Twenty minutes later, the serum potassium drops to 5.9 mEq/L. Which cellular mechanism explains this rapid decrease, and what would you find if you measured urine potassium output during this time?
A type 2 diabetic patient is prescribed rapid-acting insulin lispro with meals. The nurse asks whether to give it 30 minutes before meals (like regular insulin) or immediately before. What is the correct answer, and what is the pharmacokinetic rationale?
Rank the following insulins from shortest to longest duration of action: glargine, lispro, NPH, regular insulin. Then identify which one has NO significant peak effect and explain why that matters clinically.

Related topics

Type 1 Diabetes Mellitus Hypothalamic-Pituitary-Adrenal (HPA) Axis Hypothalamic-Pituitary-Thyroid (HPT) Axis Hypothalamic-Pituitary-Gonadal (HPG) Axis Hormone Signaling (Peptide vs Steroid)

See how your Anki deck covers this topic.

Upload your deck for a free audit →